APG-1842 / Ascentage Pharma - LARVOL DELTA

Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors (AACR 2022) - "Consistent with the cellular results, APG-1842 dose dependently inhibited ERK1/2 and S6 phosphorylation in xenografts after 6 and 24 hours of treatment, correlating with systemic and tumor drug exposures. Significant antitumor activity of APG-1842 was also confirmed in a panel of 8 KRASG12C-mutated patient-derived xenograft models derived from patient samples of lung, colorectal, and gastric cancers.Collectively, these preclinical results suggest that APG-1842 is a potent, bioavailable, and highly selective KRASG12C inhibitor, laying a foundation for clinical development of this agent for patients with KRASG12C-mutant solid tumors."

Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 (PRNewswire) - "Ascentage Pharma...announced that it has presented the latest results from six preclinical studies of the company's five investigational drug candidates...at the 2022 American Association for Cancer Research (AACR) Annual Meeting....The preclinical study suggests that APG-2449 combined with CDK4/6 inhibitors may have therapeutic potential in mesothelioma and may warrant future clinical development....APG-5918 showed definitive in vitro and in vivo target engagement and on-target antitumor activity. APG-5918 demonstrated strong PD/PK correlation in mice bearing KARPAS-422 xenograft tumors....Our data provide the preclinical evidence for clinical development of APG-1842 in patients with KRASG12C-mutant solid tumors."

Preclinical • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • Thoracic Cancer

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 (PRNewswire) - "Ascentage Pharma...announced that the results from six preclinical studies of the company's five drug candidates: the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two key products of the company's apoptosis-targeted pipeline as well as the FAK inhibitor APG-2449, the EED inhibitor APG-5918 and the KRAS Inhibitor APG-1842, have been selected for presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, and are already published on AACR's official website."

Preclinical • Hematological Malignancies • Lung Cancer • Mesothelioma • Multiple Myeloma • Oncology • Solid Tumor • Thoracic Cancer